

Special Issue

Antimicrobial Resistance and Antimicrobial Therapy of Clinically Relevant Bacteria

Message from the Guest Editors

Antimicrobial resistance is a public health problem of major importance, and the World Health Organization has warned that the current antibiotic armamentarium is not sufficient to face future challenges. Untreatable infections could emerge on a large scale, and the world may experience in some cases dramatic situations of the pre-antibiotic era. Already, clinicians in endemic areas routinely encounter patients with infections that do not respond to available treatments, and laboratories often report multidrug-resistant (MDR) or even pan-drug-resistant (PDR) bacteria. Continuous monitoring of the resistance mechanisms' epidemiology as well as knowledge regarding treatment options for clinically relevant bacteria are of great interest to health-care professionals. This Special Issue seeks manuscript submissions that further our understanding of antimicrobial resistance in clinically relevant bacteria, improvements in the detection of these mechanisms in laboratory practice as well as treatment solutions and observations. Submissions on the development of new antibiotic compounds or the in-vitro susceptibility of relevant bacteria to these compounds are especially encouraged.

Guest Editors

Dr. Georgios Meletis

Dr. Lemonia Skoura

Dr. Efthymia Protonotariou

Deadline for manuscript submissions

closed (29 February 2024)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/121935

Antibiotics
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(General Pharmacology, Toxicology and Pharmaceutics)